Rice Hall James & Associates LLC Trims Stake in Urogen Pharma $URGN

Rice Hall James & Associates LLC lessened its stake in Urogen Pharma (NASDAQ:URGN) by 10.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 259,143 shares of the company’s stock after selling 28,731 shares during the period. Rice Hall James & Associates LLC’s holdings in Urogen Pharma were worth $5,170,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in URGN. RA Capital Management L.P. purchased a new position in Urogen Pharma in the first quarter valued at $35,461,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Urogen Pharma by 216.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company’s stock valued at $48,227,000 after acquiring an additional 2,983,368 shares during the period. Soleus Capital Management L.P. purchased a new position in shares of Urogen Pharma in the 2nd quarter valued at about $29,934,000. SG Americas Securities LLC raised its holdings in Urogen Pharma by 607.1% in the 2nd quarter. SG Americas Securities LLC now owns 1,149,081 shares of the company’s stock worth $15,742,000 after purchasing an additional 986,567 shares during the period. Finally, Vestal Point Capital LP raised its holdings in Urogen Pharma by 32.1% in the 1st quarter. Vestal Point Capital LP now owns 2,152,957 shares of the company’s stock worth $23,812,000 after purchasing an additional 522,957 shares during the period. 91.29% of the stock is owned by hedge funds and other institutional investors.

Urogen Pharma Stock Performance

NASDAQ URGN opened at $23.03 on Friday. The business has a fifty day moving average price of $23.01 and a 200 day moving average price of $19.06. The company has a market cap of $1.08 billion, a P/E ratio of -6.66 and a beta of 1.21. Urogen Pharma has a one year low of $3.42 and a one year high of $30.00.

Urogen Pharma (NASDAQ:URGN) last released its earnings results on Thursday, November 6th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.03. The business had revenue of $27.48 million during the quarter, compared to analyst estimates of $34.09 million. Urogen Pharma had a negative net margin of 170.59% and a negative return on equity of 97,487.15%. As a group, sell-side analysts predict that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Wall Street Zen upgraded Urogen Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. D. Boral Capital reissued a “buy” rating and issued a $25.00 price target on shares of Urogen Pharma in a research note on Monday, October 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a report on Wednesday, October 8th. Finally, HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Urogen Pharma in a research report on Monday, October 27th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $32.00.

Insider Transactions at Urogen Pharma

In other news, insider Mark Schoenberg sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 19th. The stock was sold at an average price of $25.00, for a total value of $250,000.00. Following the completion of the sale, the insider directly owned 139,025 shares in the company, valued at $3,475,625. This represents a 6.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Chris Degnan sold 2,203 shares of Urogen Pharma stock in a transaction that occurred on Wednesday, October 8th. The stock was sold at an average price of $16.85, for a total value of $37,120.55. Following the transaction, the chief financial officer owned 2,280 shares in the company, valued at approximately $38,418. The trade was a 49.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 4.70% of the stock is currently owned by corporate insiders.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.